From determinants of RUNX1/ETO tetramerization to small-molecule protein-protein interaction inhibitors targeting acute myeloid leukemia

Journal of Chemical Information and Modeling

Volumn 53, Issue 9, 2013, Pages 2197-2202

  Metz, Alexander ^a   Schanda, Julia ^b   Grez, Manuel ^b   Wichmann, Christian ^b,c   Gohlke, Holger ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULES;

ACUTE MYELOID LEUKEMIA; MICROMOLAR CONCENTRATION; PROTEIN-PROTEIN COMPLEXES; PROTEIN-PROTEIN INTERACTIONS; SMALL MOLECULES; STRUCTURE-BASED; TETRAMERIZATION; VIRTUAL SCREENING;

PROTEINS;

ONCOPROTEIN; RUNX1T1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; MOLECULAR LIBRARY; PROTEIN BINDING;

ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; MYELOID LEUKEMIA; PATHOLOGY; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; TUMOR CELL LINE; DRUG EFFECTS; LEUKEMIA, MYELOID; PHARMACOLOGY;

CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; LEUKEMIA, MYELOID; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84884575096     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400332e     Document Type: Article

References (42)

1. Wichmann, C.; Becker, Y.; Chen-Wichmann, L.; Vogel, V.; Vojtkova, A.; Herglotz, J.; Moore, S.; Koch, J.; Lausen, J.; Mantele, W.; Gohlke, H.; Grez, M. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity Blood 2010, 116 (4) 603-613
2. Reikvam, H.; Hatfield, K. J.; Kittang, A. O.; Hovland, R.; Bruserud, O. Acute myeloid leukemia with the t(8;21) Translocation: Clinical consequences and biological implications J. Biomed. Biotechnol. 2011, 104631, 1-23
3. Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way Nat. Rev. Cancer 2003, 3 (2) 89-101
4. Liu, Y.; Cheney, M. D.; Gaudet, J. J.; Chruszcz, M.; Lukasik, S. M.; Sugiyama, D.; Lary, J.; Cole, J.; Dauter, Z.; Minor, W.; Speck, N. A.; Bushweller, J. H. The tetramer structure of the nervy homology two domain, NHR2, is critical for AML1/ETO's activity Cancer Cell 2006, 9 (4) 249-260
5. Shimada, A.; Taki, T.; Tabuchi, K.; Tawa, A.; Horibe, K.; Tsuchida, M.; Hanada, R.; Tsukimoto, I.; Hayashi, Y. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group Blood 2006, 107 (5) 1806-1809
6. Ptasinska, A.; Assi, S. A.; Mannari, D.; James, S. R.; Williamson, D.; Dunne, J.; Hoogenkamp, M.; Wu, M.; Care, M.; McNeill, H.; Cauchy, P.; Cullen, M.; Tooze, R. M.; Tenen, D. G.; Young, B. D.; Cockerill, P. N.; Westhead, D. R.; Heidenreich, O.; Bonifer, C. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding Leukemia 2012, 26 (1) 1829-1841
7. Rhoades, K. L.; Hetherington, C. J.; Harakawa, N.; Yergeau, D. A.; Zhou, L. M.; Liu, L. Q.; Little, M. T.; Tenen, D. G.; Zhang, D. E. Analysis of the role of AML1-ETO in leukemogenesis, using an Inducible transgenic mouse model Blood 2000, 96 (6) 2108-2115
8. Heidenreich, O.; Krauter, J.; Riehle, H.; Hadwiger, P.; John, M.; Heil, G.; Vornlocher, H. P.; Nordheim, A. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells Blood 2003, 101 (8) 3157-3163
9. Gruber, T. A.; Larson Gedman, A.; Zhang, J.; Koss, C. S.; Marada, S.; Ta, H. Q.; Chen, S. C.; Su, X.; Ogden, S. K.; Dang, J.; Wu, G.; Gupta, V.; Andersson, A. K.; Pounds, S.; Shi, L.; Easton, J.; Barbato, M. I.; Mulder, H. L.; Manne, J.; Wang, J.; Rusch, M.; Ranade, S.; Ganti, R.; Parker, M.; Ma, J.; Radtke, I.; Ding, L.; Cazzaniga, G.; Biondi, A.; Kornblau, S. M.; Ravandi, F.; Kantarjian, H.; Nimer, S. D.; Dohner, K.; Dohner, H.; Ley, T. J.; Ballerini, P.; Shurtleff, S.; Tomizawa, D.; Adachi, S.; Hayashi, Y.; Tawa, A.; Shih, L. Y.; Liang, D. C.; Rubnitz, J. E.; Pui, C. H.; Mardis, E. R.; Wilson, R. K.; Downing, J. R. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia Cancer Cell 2012, 22 (5) 683-697
10. Thiollier, C.; Lopez, C. K.; Gerby, B.; Ignacimouttou, C.; Poglio, S.; Duffourd, Y.; Guegan, J.; Rivera-Munoz, P.; Bluteau, O.; Mabialah, V.; Diop, M.; Wen, Q.; Petit, A.; Bauchet, A. L.; Reinhardt, D.; Bornhauser, B.; Gautheret, D.; Lecluse, Y.; Landman-Parker, J.; Radford, I.; Vainchenker, W.; Dastugue, N.; de Botton, S.; Dessen, P.; Bourquin, J. P.; Crispino, J. D.; Ballerini, P.; Bernard, O. A.; Pflumio, F.; Mercher, T. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models J. Exp. Med. 2012, 209 (11) 2017-2031
11. Wichmann, C.; Chen, L. P.; Heinrich, M.; Baus, D.; Pfitzner, E.; Zornig, M.; Ottmann, O. G.; Grez, M. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells Cancer Res. 2007, 67 (5) 2280-2289
12. Sun, X. J.; Wang, Z.; Wang, L.; Jiang, Y.; Kost, N.; Soong, T. D.; Chen, W. Y.; Tang, Z.; Nakadai, T.; Elemento, O.; Fischle, W.; Melnick, A.; Patel, D. J.; Nimer, S. D.; Roeder, R. G. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis Nature 2013, 500 (7460) 93-97
13. Bartel, Y.; Grez, M.; Wichmann, C. Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain Biomed. Res. Int. 2013, 2013, 297692
14. Surade, S.; Blundell, T. L. Structural biology and drug discovery of difficult targets: The limits of ligandability Chem. Biol. 2012, 19 (1) 42-50
15. Zinzalla, G.; Thurston, D. E. Targeting protein-protein interactions for therapeutic intervention: A challenge for the future Future Med. Chem. 2009, 1 (1) 65-93
16. Metz, A.; Ciglia, E.; Gohlke, H. Modulating protein-protein interactions: From structural determinants of binding to druggability prediction to application Curr. Pharm. Des. 2012, 18, 4630-4647
17. Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Hot spots: A review of the protein-protein interface determinant amino-acid residues Proteins: Struct., Funct., Bioinf. 2007, 68 (4) 803-812
18. Metz, A.; Pfleger, C.; Kopitz, H.; Pfeiffer-Marek, S.; Baringhaus, K. H.; Gohlke, H. Hot spots and transient pockets: Predicting the determinants of small-molecule binding to a protein-protein interface J. Chem. Inf. Model. 2012, 52 (1) 120-133
19. Gohlke, H.; Kiel, C.; Case, D. A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaIGDS complexes J. Mol. Biol. 2003, 330 (4) 891-913
20. Craig, I. R.; Pfleger, C.; Gohlke, H.; Essex, J. W.; Spiegel, K. Pocket-space maps to identify novel binding-site conformations in proteins J. Chem. Inf. Model. 2011, 51 (10) 2666-2679
21. Kahraman, A.; Morris, R. J.; Laskowski, R. A.; Thornton, J. M. Shape variation in protein binding pockets and their ligands J. Mol. Biol. 2007, 368 (1) 283-301
22. Perot, S.; Sperandio, O.; Miteva, M. A.; Camproux, A. C.; Villoutreix, B. O. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery Drug Discovery Today 2010, 15 (15-16) 656-667
23. Eyrisch, S.; Helms, V. Transient pockets on protein surfaces involved in protein-protein interaction J. Med. Chem. 2007, 50 (15) 3457-3464
24. Higueruelo, A. P.; Schreyer, A.; Bickerton, G. R. J.; Pitt, W. R.; Groom, C. R.; Blundell, T. L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: The TIMBAL Database Chem Biol Drug Des 2009, 74 (5) 457-467
25. Geppert, T.; Bauer, S.; Hiss, J. A.; Conrad, E.; Reutlinger, M.; Schneider, P.; Weisel, M.; Pfeiffer, B.; Altmann, K. H.; Waibler, Z.; Schneider, G. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions Angew Chem, Int Ed 2012, 51 (1) 258-261
26. Mukherjee, P.; Desai, P.; Zhou, Y. D.; Avery, M. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening J Chem Inf Model 2010, 50 (5) 906-923
27. Kim, I. C.; Hamilton, A. D. Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix Org. Lett. 2006, 8 (9) 1751-1754
28. Yin, H.; Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents Angew. Chem., Int. Ed. 2005, 44 (27) 4130-4163
29. Davis, J. M.; Truong, A.; Hamilton, A. D. Synthesis of a 2,3′;6′,3″-terpyridine scaffold as an alpha-helix mimetic Org. Lett. 2005, 7 (24) 5405-5408
30. Cummings, C. G.; Hamilton, A. D. Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics Curr. Opin. Chem. Biol. 2010, 14 (3) 341-346
31. Irwin, J. J.; Shoichet, B. K. ZINC -A free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45 (1) 177-182
32. OEChem, version 1.7.2; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2009.
33. McKay, I. A.; Kirby, L.; Volyanik, E. V.; Kumar, V.; Wong, P. W. Y.; Bustin, S. A. An enzyme-linked immunosorbent assay for the detection of agents which interfere with the DNA binding activities of transcription factors-Exemplified by NF-IL6 Anal. Biochem. 1998, 265 (1) 28-34
34. Bender, A.; Mussa, H. Y.; Glen, R. C.; Reiling, S. Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): Evaluation of performance J. Chem. Inf. Comput. Sci. 2004, 44 (5) 1708-1718
35. Davey, D. D.; Adler, M.; Arnaiz, D.; Eagen, K.; Erickson, S.; Guilford, W.; Kenrick, M.; Morrissey, M. M.; Ohlmeyer, M.; Pan, G.; Paradkar, V. M.; Parkinson, J.; Polokoff, M.; Saionz, K.; Santos, C.; Subramanyam, B.; Vergona, R.; Wei, R. G.; Whitlow, M.; Ye, B.; Zhao, Z. S.; Devlin, J. J.; Phillips, G. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors J. Med. Chem. 2007, 50 (6) 1146-1157
36. Wu, C. C.; Li, T. K.; Farh, L.; Lin, L. Y.; Lin, T. S.; Yu, Y. J.; Yen, T. J.; Chiang, C. W.; Chan, N. L. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 2011, 333 (6041) 459-462
37. Wirth, M.; Zoete, V.; Michielin, O.; Sauer, W. H. B. SwissBioisostere: A database of molecular replacements for ligand design Nucleic Acids Res. 2013, 41 (D1) D1137-D1143
38. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450 (7172) 1001-1009
39. Kaoud, T. S.; Yan, C.; Mitra, S.; Tseng, C. C.; Jose, J.; Taliaferro, J. M.; Tuohetahuntila, M.; Devkota, A.; Sammons, R.; Park, J.; Park, H.; Shi, Y.; Hong, J.; Ren, P.; Dalby, K. N. From in silico discovery to intra-cellular activity: Targeting JNK-protein interactions with small molecules ACS Med. Chem. Lett. 2012, 3 (9) 721-725
40. Elsasser, A.; Franzen, M.; Kohlmann, A.; Weisser, M.; Schnittger, S.; Schoch, C.; Reddy, V. A.; Burel, S.; Zhang, D. E.; Ueffing, M.; Tenen, D. G.; Hiddemann, W.; Behre, G. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner Oncogene 2003, 22 (36) 5646-5657
41. Gao, F. H.; Wang, Q.; Wu, Y. L.; Li, X.; Zhao, K. W.; Chen, G. Q. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression Biochem. Biophys. Res. Commun. 2007, 356 (2) 505-511
42. Srivastava, V.; Negi, A. S.; Kumar, J. K.; Gupta, M. M.; Khanuja, S. P. S. Plant-based anticancer molecules: A chemical and biological profile of some important leads Bioorg. Med. Chem. 2005, 13 (21) 5892-5908